Immutep Limited - American Depositary Shares (IMMP)
1.5100
-0.1000 (-6.21%)
NASDAQ · Last Trade: Apr 5th, 9:15 AM EDT
Detailed Quote
Previous Close
1.610
Open
1.590
Bid
1.500
Ask
1.710
Day's Range
1.450 - 1.610
52 Week Range
1.450 - 3.335
Volume
173,439
Market Cap
1.13B
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
75,866
Chart
About Immutep Limited - American Depositary Shares (IMMP)
Immutep Ltd is a biotechnology company that focuses on developing innovative immunotherapy treatments for cancer and autoimmune diseases. The company is primarily engaged in the research and development of products that harness the power of the immune system to better target and eliminate cancer cells. Immutep's pipeline includes both monoclonal antibodies and other therapeutic agents designed to enhance immune response, with an emphasis on delivering effective treatments for patients with unmet medical needs. Through partnerships and collaborations, Immutep aims to pioneer new approaches to cancer therapy and improve patient outcomes. Read More
Immutep announces results from Cohort B of the TACTI-003 Phase 2b trial. The combination of eftilagimod alfa and Merck's Keytruda shows a 35.5% ORR and 58.1% DCR in PD-L1 negative head and neck cancer patients, with no new safety concerns.
Immutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line treatment of HNSCC patients without PD-L1 expression. Final data expected in H1 CY2024.
Immutep releases promising safety and efficacy data for 90mg eftilagimod alpha combined with paclitaxel in HR+/HER2- metastatic breast cancer. No serious adverse events were reported, and a 50% overall response rate was observed in the Phase 2/3 trial.
